Lenalidomide proved effective in multisystem Langerhans cell histiocytosis

SZTURZ, Petr, Zdeněk ADAM, Zdeněk ŘEHÁK, Renata KOUKALOVÁ, Radka ŠLAISOVÁ, Olga STEHLÍKOVÁ, Jana CHOVANCOVÁ, Martin KLABUSAY, Marta KREJČÍ, Luděk POUR, Roman HÁJEK and Jiří MAYER. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncologica. 2012, vol. 51, No 3, p. 412-415. ISSN 0284-186X. Available from: https://dx.doi.org/10.3109/0284186X.2011.631581.

Basic information

• Original name: Lenalidomide proved effective in multisystem Langerhans cell histiocytosis
• Authors: SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Zdeněk ŘEHÁK (203 Czech Republic), Renata KOUKALOVÁ (203 Czech Republic), Radka ŠLAISOVÁ (203 Czech Republic, belonging to the institution), Olga STEHLÍKOVÁ (203 Czech Republic, belonging to the institution), Jana CHOVANCOVÁ (203 Czech Republic), Martin KLABUSAY (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
• Edition: Acta Oncologica, 2012, 0284-186X.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Norway
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 2.867
• RIV identification code: RIV/00216224:14110/12:00059809
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3109/0284186X.2011.631581
• UT WoS: 000302731800022
• Keywords in English: Langerhans cell histiocytosis; lenalidomide; PET/CT
• Tags: International impact

Abstract

Langerhans cell histiocytosis (LCH) is a rare idiopathic disease with diverse clinical manifestations ranging from a single osteolytic lesion to generalized disease. Various treatment regimens have been proposed for the multisystem type, however, with inconsistent outcomes. Herein we are the first to report on a therapy effect of a lenalidomide-based regimen in a patient with repeatedly relapsed aggressive form of multisystem LCH.

Links

• LC06027, research and development project: Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

• MSM0021622434, plan (intention): Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

• NS9671, research and development project: Name: Stanovení hladiny cytokinů a kostimulačních molekul v plasmě, kostní dřeni, leukocytech a nádorových buňkách nemocných s hematologickými malignitami a jejich vztah k aktivitě nemoci, transplantaci krvetvorby, rozvoji komplikací (GvHD) a riziku relapsu.

Investor: Ministry of Health of the CR

• NT11154, research and development project: Name: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu

Investor: Ministry of Health of the CR